Literature DB >> 18473440

Bisphosphonate derivatives of nucleoside antimetabolites: hydrolytic stability and hydroxyapatite adsorption of 5'-beta,gamma-methylene and 5'-beta,gamma-(1-hydroxyethylidene) triphosphates of 5-fluorouridine and ara-cytidine.

Mikko Ora1, Tuomas Lönnberg, Diana Florea-Wang, Shawn Zinnen, Alexander Karpeisky, Harri Lönnberg.   

Abstract

Kinetics of the hydrolytic reactions of four bisphosphonate derivatives of nucleoside antimetabolites, viz., 5-fluorouridine 5'-beta,gamma-(1-hydroxyethylidene) triphosphate ( 4), 5-fluorouridine 5'-beta,gamma-methylene triphosphate ( 5), ara-cytidine 5'-beta,gamma-(1-hydroxyethylidene) triphosphate ( 6), and ara-cytidine 5'-beta,gamma-methylene triphosphate ( 7), have been studied over a wide pH range (pH 1.0-8.5) at 90 degrees C. With each compound, the disappearance of the starting material was accompanied by formation of the corresponding nucleoside 5'-monophosphate, the reaction being up to 2 orders of magnitude faster with the beta,gamma-(1-hydroxyethylidene) derivatives ( 4, 6) than with their beta,gamma-methylene counterparts ( 5, 7). With compound 7, deamination of the cytosine base competed with the phosphate hydrolysis at pH 3-6. The measurements at 37 degrees C (pH 7.4) in the absence and presence of divalent alkaline earth metal ions (Mg (2+) and Ca (2+)) showed no sign of metal ion catalysis. Under these conditions, the initial product, nucleoside 5'-monophosphate, underwent rapid dephosphorylation to the corresponding nucleoside. Hydrolysis of the beta,gamma-methylene derivatives ( 5, 7) to the corresponding nucleoside 5'-monophosphates was markedly faster in mouse serum than in aqueous buffer (pH 7.4), the rate-acceleration being 5600- and 3150-fold with 5 and 7, respectively. In human serum, the accelerations were 800- and 450-fold compared to buffer. In striking contrast, the beta,gamma-(1-hydroxyethylidene) derivatives did not experience a similar decrease in hydrolytic stability. The stability in human serum was comparable to that in aqueous buffer (tau 1/2 = 17 and 33 h with 4 and 6, respectively), and on going to mouse serum, a 2- to 4-fold acceleration was observed. To elucidate the mineral-binding properties of 4- 7, their retention on a hydroxyapatite column was studied and compared to that of zoledronate ( 1a) and nucleoside mono-, di-, and triphosphates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18473440     DOI: 10.1021/jo800317e

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  4 in total

1.  Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone.

Authors:  Jivan N Yewle; David A Puleo; Leonidas G Bachas
Journal:  Bioconjug Chem       Date:  2011-12-05       Impact factor: 4.774

2.  A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.

Authors:  Monica M Reinholz; Shawn P Zinnen; Amylou C Dueck; David Dingli; Gregory G Reinholz; Leslie A Jonart; Kathleen A Kitzmann; Amy K Bruzek; Vivian Negron; Abdalla K Abdalla; Bonnie K Arendt; Anthony J Croatt; Luis Sanchez-Perez; David P Sebesta; Harri Lönnberg; Toshiyuki Yoneda; Karl A Nath; Diane F Jelinek; Stephen J Russell; James N Ingle; Thomas C Spelsberg; Henry B F Hal Dixon; Alexander Karpeisky; Wilma L Lingle
Journal:  Bone       Date:  2010-03-15       Impact factor: 4.398

3.  First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease.

Authors:  Shawn Patrick Zinnen; Alexander Karpeisky; Daniel D Von Hoff; Larisa Plekhova; Alexander Alexandrov
Journal:  Oncologist       Date:  2018-11-09

Review 4.  Bisphosphonate conjugation for bone specific drug targeting.

Authors:  Kristen B Farrell; Alexander Karpeisky; Douglas H Thamm; Shawn Zinnen
Journal:  Bone Rep       Date:  2018-07-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.